The Fetal Care Center of Southern California connects experts in maternal-fetal medicine and pediatrics in a single location at CHOC.
Twenty-four years ago, Dr. Michael Muhonen, treated a baby born with what essentially was a traumatic brain injury. That baby, Eric Rhee, is now 24 and headed off to medical school.
Ryder Montano is the third and youngest CHOC patient with a movement disorder to undergo a procedure called deep brain stimulation (DBS).
With Father’s Day near, two CHOC providers reflect on the challenge of balancing their demanding and often emotionally exhausting work with fatherhood.
Dr. Mary Zupanc has achieved many superlatives over her long career in medicine; accolades and awards have followed. But the co-director of the CHOC Neuroscience Institute and UCI professor of pediatrics and neurology considers the Arnold P. Gold Foundation Humanism in Medicine Award her highest honor of all.
Dr. Suresh Magge, medical director of neurosurgery at CHOC, and co-medical director of the CHOC Neuroscience Institute, discusses four surgeries he is excited about as a pediatric neurosurgeon.
In one of the first such large studies of its kind in neonatology, Dr. Shafer is researching the prevalence of diagnostic errors and the ethical responsibilities of providers to disclose such errors to families of impacted NICU patients.
After years of planning, CHOC’s neonatal intensive care unit (NICU), in a partnership with UC Irvine Health, has hired its first senior fellow in neonatal cardiovascular ICU and hemodynamics. The fourth-year fellowship position is one of only two such ones in the western U.S. and the first-ever senior level fellowship at CHOC in any specialty.
The odds were stacked against Hope when she was born prematurely at 31 weeks and five days, weighing just 2 pounds, 3 ounces. Today, Hope is alive thanks to a team of doctors, nurses and others who cared for her throughout a four month stay on CHOC’s neonatal intensive care unit (NICU) and cardiovascular intensive care unit (CVICU).
Children who experience seizures associated with Dravet syndrome have a new medication option, thanks to research at CHOC that helped gain the recent approval of the FDA.